

This Technical Note explores why circulating tumor DNA (ctDNA) fraction is a key interpretive parameter in liquid biopsy analysis, from interpreting negative results to supporting treatment response assessment and resistance evolution research.
We highlight how MSK-ACCESS® powered with SOPHiA DDM™ uses a matched tumor-normal approach and the SESAME AI agent for robust ctDNA estimation within one fully integrated workflow. Learn how ctDNA fraction adds context to the interpretation of variants and complex biomarkers, including microsatellite instability (MSI).
MSK-ACCESS® powered with SOPHiA DDM™ is for Research Use Only (RUO). RUO results must not be used for clinical diagnosis or patient management.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.